Aesica Appoints Chris Gowland as Chief Operating Officer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aesica Appoints Chris Gowland as Chief Operating Officer


Aesica, a global contract development and manufacturing organization (CDMO), announced that it has appointed Chris Gowland as Chief Operating Officer. This new position was created to further enhance the company’s operational performance in APIs and formulated product manufacturing services.

As COO, Gowland has overall responsibility for all operating strategy, which includes setting of operational standards and driving continuous improvement across the company’s manufacturing capabilities in API and formulated products.

He will also be responsible for the management of capital expenditure, procurement of materials and services, managing the supply chain, and overseeing capacity expansion across the group to ensure that Aesica meets full customer demand whilst delivering maximum service value.

Gowland is now in charge of the operational performance and general management of all Aesica manufacturing sites including Queenborough and Cramlington in the UK, Monheim and Zwickau in Germany, and Pianezza in Italy.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here